NPF Fellows Symposium

Sunvozertinib has received accelerated approval for use in advanced or metastatic non–small lung cancer harboring EGFR exon 20 insertion mutations.

In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.

Oncologic therapies approved in June included indications in genitourinary, lung, and hematologic, and head and neck cancers.

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

Anlotinib combined with immune checkpoint inhibitors may benefit patients with extensive-stage small cell lung cancer treated with prior immunotherapy.

Planning for adverse effects early on helps patients prepare for what lies ahead, says Michelle Kirschner, MSN, RN, ACNP, APRN-BC.